المؤلفون: Recio, Fernando, Scalise, Carly Bess, Loar, Paul, Lumish, Melissa, Berman, Tara, Peddada, Abhinand, Kalashnikova, Ekaterina, Rivero-Hinojosa, Samuel, Beisch, Tricia, Nicosia, Brittany, Farmer, Tiffany, Dutta, Punashi, Malhotra, Meenakshi, ElNaggar, Adam C., Liu, Minetta C., Vaccarello, Luis, Holloway, Robert W.

المصدر: Gynecologic Oncology ; volume 182, page 63-69 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2023.12.025Test
https://api.elsevier.com/content/article/PII:S0090825823016311?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825823016311?httpAccept=text/plainTest

المؤلفون: Friedman, Claire F., D'Souza, Anishka, Bello Roufai, Diana, Tinker, Anna V., de Miguel, Maria, Gambardella, Valentina, Goldman, Jonathan, Loi, Sherene, Melisko, Michelle E., Oaknin, Ana, Spanggaard, Iben, Shapiro, Geoffrey I., ElNaggar, Adam C., Panni, Stefano, Ravichandran, Vignesh, Frazier, Aimee L., DiPrimeo, Daniel, Eli, Lisa D., Solit, David B.

المساهمون: Cycle for Survival, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Puma Biotechnology Inc

المصدر: Gynecologic Oncology ; volume 181, page 162-169 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2023.12.004Test
https://api.elsevier.com/content/article/PII:S0090825823016013?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825823016013?httpAccept=text/plainTest

المؤلفون: Oaknin, Ana, Friedman, Claire F, Roman, Lynda D, D’Souza, Anishka, Brana, Irene, Bidard, François-Clement, Goldman, Jonathan, Alvarez, Edwin A, Boni, Valentina, ElNaggar, Adam C, Passalacqua, Rodolfo, T.M., Khanh, Santin, Alessandro D, Keyvanjah, Kiana, Xu, Feng, Eli, Lisa D, Lalani, Alshad S, Bryce, Richard P, Hyman, David M, Meric-Bernstam, Funda, Solit, David B, Monk, Bradley J

المصدر: Gynecologic Oncology. 159(1)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Administration, Oral, Adult, Diarrhea, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Mutation, Nausea, Neoplasm Recurrence, Local, Progression-Free Survival, Protein Kinase Inhibitors, Quinolines, Receptor, ErbB-2, Response Evaluation Criteria in Solid Tumors, Severity of Illness Index, Uterine Cervical Neoplasms, Cervical cancer, HER2 mutant, Neratinib, Clinical trial, Tyrosine kinase inhibitor, Receptor, erbB-2, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine

الوصف: ObjectiveSomatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active in multiple HER2-mutant cancers. SUMMIT is a phase II basket trial investigating the efficacy and safety of neratinib in solid tumors.MethodsPatients with HER2-mutant, persistent, metastatic/recurrent cervical cancer with disease progression after platinum-based treatment for advanced/recurrent disease received oral neratinib 240 mg/day with mandatory loperamide prophylaxis during cycle 1. The primary endpoint was confirmed objective response rate (ORR). Secondary endpoints included: response duration (DOR); clinical benefit rate (CBR); progression-free survival (PFS); overall survival (OS); safety.ResultsSixteen eligible patients were enrolled; 10 (62.5%) had endocervical adenocarcinoma. The most common HER2 mutation was S310F (63% of patients). Three of 12 RECIST-measurable patients had confirmed partial responses (ORR 25%; 95%CI 5.5-57.2%); 3 had stable disease ≥16 weeks (CBR 50%; 95%CI 21.1-78.9%). DOR for responders were 5.6, 5.9, and 12.3 months. Median PFS was 7.0 months (95%CI 0.7-18.3 months); median OS was 16.8 months (95%CI 4.1-NE months). Diarrhea (75%), nausea (44%), and decreased appetite (38%) were the most common adverse events. One patient (6%) reported grade 3 diarrhea. There were no grade 4 events, and no diarrhea-related treatment discontinuations.ConclusionsNeratinib monotherapy showed evidence of activity in heavily pretreated patients with HER2-mutant cervical cancer, with no new safety signals. Given the few effective options for cervical cancer after platinum-based therapy failure, neratinib warrants further investigation in this molecularly defined patient population.Trial registration numberNCT01953926 (ClinicalTrials.gov), 2013-002872-42 (EudraCT).

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/83m8v37nTest

المؤلفون: Lindskrog, Sia Viborg, Birkenkamp-Demtröder, Karin, Nordentoft, Iver Kristiansen, Laliotis, George, Lamy, Philippe, Christensen, Emil, Renner, Derrick, Andreasen, Tine Ginnerup, Lange, Naja, Sharma, Shruti, ElNaggar, Adam C., Liu, Minetta C., Sethi, Himanshu, Aleshin, Alexey, Agerbæk, Mads, Jensen, Jørgen Bjerggaard, Dyrskjøt, Lars

المصدر: Lindskrog , S V , Birkenkamp-Demtröder , K , Nordentoft , I K , Laliotis , G , Lamy , P , Christensen , E , Renner , D , Andreasen , T G , Lange , N , Sharma , S , ElNaggar , A C , Liu , M C , Sethi , H , Aleshin , A , Agerbæk , M , Jensen , J B & Dyrskjøt , L 2023 , ' Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up ' , Clinical Cancer Research , vol. ....

العلاقة: https://pure.au.dk/portal/en/publications/d351ea2b-c961-421c-868f-d55c8493aff3Test

الإتاحة: https://doi.org/10.1158/1078-0432.CCR-23-1860Test
https://pure.au.dk/portal/en/publications/d351ea2b-c961-421c-868f-d55c8493aff3Test

المؤلفون: Simmons, Daniel, Blank, Stephanie V., ElNaggar, Adam C., Chastek, Benjamin, Bunner, Scott H., McLaurin, Kimmie

المساهمون: AstraZeneca

المصدر: Advances in Therapy ; volume 39, issue 6, page 2544-2561 ; ISSN 0741-238X 1865-8652

مصطلحات موضوعية: Pharmacology (medical), General Medicine

الإتاحة: https://doi.org/10.1007/s12325-022-02086-5Test

المؤلفون: Cadoo, Karen, Simpkins, Fiona, Mathews, Cara, Liu, Ying L., Provencher, Diane, McCormick, Colleen, ElNaggar, Adam C., Altman, Alon D., Gilbert, Lucy, Black, Destin, Kabil, Nashwa, Bennett, James, Munley, Jiefen, Aghajanian, Carol

المساهمون: Merck Sharp and Dohme, AstraZeneca, Merck, Memorial Sloan-Kettering Cancer Center

المصدر: Gynecologic Oncology ; volume 166, issue 3, page 425-431 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2022.06.017Test
https://api.elsevier.com/content/article/PII:S0090825822004218?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825822004218?httpAccept=text/plainTest

المؤلفون: Hou, June Y., Chapman, Jocelyn S., Kalashnikova, Ekaterina, Pierson, William, Smith-McCune, Karen, Pineda, Geovanni, Vattakalam, Reena Marie, Ross, Alexandra, Mills, Meredith, Suarez, Carlos J., Davis, Tracy, Edwards, Robert, Boisen, Michelle, Sawyer, Sarah, Wu, Hsin-Ta, Dashner, Scott, Aushev, Vasily N., George, Giby V., Malhotra, Meenakshi, Zimmermann, Bernhard, Sethi, Himanshu, ElNaggar, Adam C., Aleshin, Alexey, Ford, James M.

المصدر: Gynecologic Oncology ; volume 167, issue 2, page 334-341 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2022.09.004Test
https://api.elsevier.com/content/article/PII:S009082582200590X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S009082582200590X?httpAccept=text/plainTest

المؤلفون: Lindskrog, Sia Viborg, Laliotis, George, Birkenkamp-Demtröder, Karin, Nordentoft, Iver Kristiansen, Lamy, Philippe, Z. White, Elshaddai, Pajak, Natalia, Andreasen, Tine Ginnerup, Dutta, Punashi, Malhotra, Meenakshi, Sharma, Shruti, Calhoun, Mark, ElNaggar, Adam C., Liu, Minetta C., Agerbæk, Mads Ovesen, Jensen, Jørgen Bjerggaard, Dyrskjøt, Lars

المصدر: Lindskrog , S V , Laliotis , G , Birkenkamp-Demtröder , K , Nordentoft , I K , Lamy , P , Z. White , E , Pajak , N , Andreasen , T G , Dutta , P , Malhotra , M , Sharma , S , Calhoun , M , ElNaggar , A C , Liu , M C , Agerbæk , M O , Jensen , J B & Dyrskjøt , L 2023 , ' 5600 / 24 : Utility of circulating tumor DNA and transcriptomic profiling in predicting outcome in muscle invasive bladder cancer patients ....

العلاقة: https://pure.au.dk/portal/en/publications/8b3253f3-ca20-4f3b-af78-6168a5a225b7Test

الإتاحة: https://pure.au.dk/portal/en/publications/8b3253f3-ca20-4f3b-af78-6168a5a225b7Test
https://www.abstractsonline.com/pp8/#!/10828/presentation/4585Test

المؤلفون: Randall, Leslie M., O'Malley, David M., Monk, Bradley J., Coleman, Robert L., Gaillard, Stephanie, Adams, Sarah, Duska, Linda R., Dalton, Heather, Holloway, Robert W., Huang, Marilyn, Chon, Hye Sook, Cloven, Noelle G., ElNaggar, Adam C., O'Cearbhaill, Roisin E., Waggoner, Steven, Tarkar, Aarti, Striha, Alina, Nelsen, Linda M., Baines, Amanda, Samnotra, Vivek, Konstantinopoulos, Panagiotis A.

المصدر: Gynecologic Oncology ; volume 178, page 161-169 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2023.10.005Test
https://api.elsevier.com/content/article/PII:S0090825823014981?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825823014981?httpAccept=text/plainTest

المؤلفون: Arend, Rebecca, Dholakia, Jhalak, Castro, Cesar, Matulonis, Ursula, Hamilton, Erika, Jackson, Camille Gunderson, LyBarger, Kristopher, Goodman, Howard M., Duska, Linda R., Mahdi, Haider, ElNaggar, Adam C., Kagey, Michael H., Liu, Amy, Piper, Diane, Barroilhet, Lisa M., Bradley, William, Sachdev, Jasgit, Sirard, Cynthia A., O'Malley, David M., Birrer, Michael

المصدر: Gynecologic Oncology ; volume 172, page 82-91 ; ISSN 0090-8258

مصطلحات موضوعية: Obstetrics and Gynecology, Oncology

الإتاحة: https://doi.org/10.1016/j.ygyno.2023.03.013Test
https://api.elsevier.com/content/article/PII:S0090825823001488?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0090825823001488?httpAccept=text/plainTest